Hormonal therapy of breast cancer (Q60357515)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

review article

1 reference

title

Hormonal therapy of breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

G Y Locker

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 June 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

221-240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

Advanced breast cancer - additive hormonal therapy

5 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

The use of estrogens and androgens in advanced mammary cancer; clinical and laboratory study of 105 female patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Hormonal treatment of cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Oophorectomy/adrenalectomy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Transsphenoidal hypophysectomy in breast cancer.Evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Endocrinologically incomplete transethmoidal trans-sphenoidal hypophysectomy with relief of bone pain in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Corticosteroids for elderly patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Functional domains of the human estrogen receptor

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

The human estrogen receptor has two independent nonacidic transcriptional activation functions

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

William L. McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Hormone dependency of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

The value of estrogen and progesterone receptors in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Breast cancers negative for estrogen receptor but positive for progesterone receptor, a true entity?

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Oestrogen-responsive human breast cancer in long term tissue culture

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Mechanisms of action of endocrine treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

A new interpretation of antiestrogen action

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone sulfate to estradiol in the MCF-7 mammary cancer cell line

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Regulation and role of TGF beta production in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Mechanisms of hormone resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

How do breast cancers become hormone resistant?

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Multiple splicing variants of the estrogen receptor are present in individual human breast tumors

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen in premenopausal patients with metastatic breast cancer: a review

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Adjuvant Tamoxifen for male breast cancer (MBC)

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Weight gain after primary surgery for breast cancer--effect of tamoxifen

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen-induced hypercalcemia in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Hormone-induced tumor flare

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen-associated eye disease. A review

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Coronary heart disease mortality and adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Potential role of tamoxifen in prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Phase I study of toremifene in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Clinical potential of new antiestrogens

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Gonadotropin-releasing hormone binding sites in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Phase II study of goserelin for patients with postmenopausal metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Aromatase inhibitor development for treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Aromatase inhibition for breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

First generation aromatase inhibitors--aminoglutethimide and testololactone

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Second generation aromatase inhibitor--4-hydroxyandrostenedione

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Progestin therapy of breast cancer: comparison of agents

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary carcinoma cell growth

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Progestin regulation of insulin and insulin-like growth factor I receptors in cultured human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Aust

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: A prospective randomized study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

New endocrine therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

Estrogen receptors: new perspectives in breast cancer management.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90051-2

7 January 2021

10.1016/S0305-7372(98)90051-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9767736 AND SRC:MED&resulttype=core&format=json

5 December 2019

1 reference